Show simple item record

dc.contributor.authorBavetsias, V
dc.contributor.authorLanigan, RM
dc.contributor.authorRuda, GF
dc.contributor.authorAtrash, B
dc.contributor.authorMcLaughlin, MG
dc.contributor.authorTumber, A
dc.contributor.authorMok, NY
dc.contributor.authorLe Bihan, Y-V
dc.contributor.authorDempster, S
dc.contributor.authorBoxall, KJ
dc.contributor.authorJeganathan, F
dc.contributor.authorHatch, SB
dc.contributor.authorSavitsky, P
dc.contributor.authorVelupillai, S
dc.contributor.authorKrojer, T
dc.contributor.authorEngland, KS
dc.contributor.authorSejberg, J
dc.contributor.authorThai, C
dc.contributor.authorDonovan, A
dc.contributor.authorPal, A
dc.contributor.authorScozzafava, G
dc.contributor.authorBennett, JM
dc.contributor.authorKawamura, A
dc.contributor.authorJohansson, C
dc.contributor.authorSzykowska, A
dc.contributor.authorGileadi, C
dc.contributor.authorBurgess-Brown, NA
dc.contributor.authorvon Delft, F
dc.contributor.authorOppermann, U
dc.contributor.authorWalters, Z
dc.contributor.authorShipley, J
dc.contributor.authorRaynaud, FI
dc.contributor.authorWestaway, SM
dc.contributor.authorPrinjha, RK
dc.contributor.authorFedorov, O
dc.contributor.authorBurke, R
dc.contributor.authorSchofield, CJ
dc.contributor.authorWestwood, IM
dc.contributor.authorBountra, C
dc.contributor.authorMüller, S
dc.contributor.authorvan Montfort, RLM
dc.contributor.authorBrennan, PE
dc.contributor.authorBlagg, J
dc.date.accessioned2020-06-22T15:47:39Z
dc.date.issued2016-02-25
dc.identifier.citationJournal of medicinal chemistry, 2016, 59 (4), pp. 1388 - 1409
dc.identifier.issn0022-2623
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3767
dc.identifier.eissn1520-4804
dc.identifier.doi10.1021/acs.jmedchem.5b01635
dc.description.abstractWe report the discovery of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysine demethylase (KDM) inhibitors which bind to Fe(II) in the active site. Substitution from C4 of the pyrazole moiety allows access to the histone peptide substrate binding site; incorporation of a conformationally constrained 4-phenylpiperidine linker gives derivatives such as 54j and 54k which demonstrate equipotent activity versus the KDM4 (JMJD2) and KDM5 (JARID1) subfamily demethylases, selectivity over representative exemplars of the KDM2, KDM3, and KDM6 subfamilies, cellular permeability in the Caco-2 assay, and, for 54k, inhibition of H3K9Me3 and H3K4Me3 demethylation in a cell-based assay.
dc.formatPrint-Electronic
dc.format.extent1388 - 1409
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCaco-2 Cells
dc.subjectHumans
dc.subjectPyrimidinones
dc.subjectNuclear Proteins
dc.subjectRepressor Proteins
dc.subjectEnzyme Inhibitors
dc.subjectCell Membrane Permeability
dc.subjectJumonji Domain-Containing Histone Demethylases
dc.title8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
dc.typeJournal Article
rioxxterms.versionofrecord10.1021/acs.jmedchem.5b01635
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of medicinal chemistry
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.publication-statusPublished
pubs.volume59
pubs.embargo.termsNot known
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
icr.researchteamMedicinal Chemistry 1
icr.researchteamSarcoma Molecular Pathology
icr.researchteamHit Discovery & Structural Design
dc.contributor.icrauthorBavetsias, Vassilios
dc.contributor.icrauthorLe Bihan, Yann-Vai
dc.contributor.icrauthorPal, Akos
dc.contributor.icrauthorShipley, Janet
dc.contributor.icrauthorRaynaud, Florence
dc.contributor.icrauthorBurke, Rosemary
dc.contributor.icrauthorVan Montfort, Robert


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0